Lipid Anti-Lipid Antibody Responses Correlate with Disease Activity in Systemic Lupus Erythematosus

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Jovanović, Vojislav ^a   Abdul Aziz, Nurhuda ^a   Lim, Yan Ting ^a   Ng Ai Poh, Amanda ^a   Jin Hui Chan, Sherlynn ^a   Ho Xin Pei, Eliza ^a   Lew, Fei Chuin ^a   Shui, Guanghou ^a   Jenner, Andrew M ^d   Bowen, Li ^a   McKinney, Eoin F ^b,c   Lyons, Paul A ^b,c   Kemeny, Michael D ^a   Smith, Kenneth G C ^b,c   Wenk, Markus R ^a   MacAry, Paul A ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

24 HYDROXYCHOLESTEROL; 7 BETA HYDROCHOLESTEROL; 7 BETA HYDROCHOLESTEROL ANTIBODY; 7 KETOHYDROCHOLESTEROL; 7 KETOHYDROCHOLESTEROL ANTIBODY; ANTIBODY; CARDIOLIPIN; CARDIOLIPIN ANTIBODY; CHOLESTEROL DERIVATIVE; FENOFIBRATE; IMMUNOGLOBULIN G; LATHOSTEROL; LATHOSTEROL ANTIBODY; LIPID; LIPID ANTIBODY; PHOSPHATIDYLSERINE; PHOSPHATIDYLSERINE ANTIBODY; PRAVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE EXACERBATION; DISEASE MARKER; DISEASE SEVERITY; HUMAN; HUMAN CELL; IMMUNOGLOBULIN BLOOD LEVEL; PROGNOSIS; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS;

AUTOANTIBODIES; BIOLOGICAL MARKERS; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; IMMUNOGLOBULIN G; LIPIDS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 84873576189     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055639     Document Type: Article

References (60)

1. Mok CC, Lau CS, (2003) Pathogenesis of systemic lupus erythematosus. J Clin Pathol 56: 481-490.
2. Tenbrock K, Juang YT, Kyttaris VC, Tsokos GC, (2007) Altered signal transduction in SLE T cells. Rheumatology (Oxford) 46: 1525-1530.
3. Jenks SA, Sanz I, (2009) Altered B cell receptor signaling in human systemic lupus erythematosus. Autoimmun Rev 8: 209-213.
4. Pascual V, Banchereau J, Palucka AK, (2003) The central role of dendritic cells and interferon-alpha in SLE. Curr Opin Rheumatol 15: 548-556.
5. Kirou KA, Salmon JE, Crow MK (2006) Soluble mediators as therapeutic targets in systemic lupus erythematosus: cytokines, immunoglobulin receptors, and the complement system. Rheum Dis Clin North Am 32: 103-119, ix.
6. Munoz LE, Gaipl US, Herrmann M, (2008) Predictive value of anti-dsDNA autoantibodies: importance of the assay. Autoimmun Rev 7: 594-597.
7. Munoz LE, Lauber K, Schiller M, Manfredi AA, Herrmann M, (2010) The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat Rev Rheumatol 6: 280-289.
8. Gaipl US, Kuhn A, Sheriff A, Munoz LE, Franz S, et al. (2006) Clearance of apoptotic cells in human SLE. Curr Dir Autoimmun 9: 173-187.
9. Niederer HA, Willcocks LC, Rayner TF, Yang W, Lau YL, et al. (2010) Copy number, linkage disequilibrium and disease association in the FCGR locus. Hum Mol Genet 19: 3282-3294.
10. Bjorkhem I, Meaney S, Diczfalusy U, (2002) Oxysterols in human circulation: which role do they have? Curr Opin Lipidol 13: 247-253.
11. Brown AJ, Jessup W, (2009) Oxysterols: Sources, cellular storage and metabolism, and new insights into their roles in cholesterol homeostasis. Mol Aspects Med 30: 111-122.
12. Lutjohann D, Breuer O, Ahlborg G, Nennesmo I, Siden A, et al. (1996) Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proc Natl Acad Sci U S A 93: 9799-9804.
13. Bjorkhem I, Lutjohann D, Diczfalusy U, Stahle L, Ahlborg G, et al. (1998) Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. J Lipid Res 39: 1594-1600.
14. Lutjohann D, Papassotiropoulos A, Bjorkhem I, Locatelli S, Bagli M, et al. (2000) Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J Lipid Res 41: 195-198.
15. Leoni V, Masterman T, Diczfalusy U, De Luca G, Hillert J, et al. (2002) Changes in human plasma levels of the brain specific oxysterol 24S-hydroxycholesterol during progression of multiple sclerosis. Neurosci Lett 331: 163-166.
16. Qin J, Goswami R, Balabanov R, Dawson G, (2007) Oxidized phosphatidylcholine is a marker for neuroinflammation in multiple sclerosis brain. J Neurosci Res 85: 977-984.
17. Seet RC, Lee CY, Lim EC, Tan JJ, Quek AM, et al. (2010) Oxidative damage in Parkinson disease: Measurement using accurate biomarkers. Free Radic Biol Med 48: 560-566.
18. Berthier A, Lemaire-Ewing S, Prunet C, Montange T, Vejux A, et al. (2005) 7-Ketocholesterol-induced apoptosis. Involvement of several pro-apoptotic but also anti-apoptotic calcium-dependent transduction pathways. FEBS J 272: 3093-3104.
19. Kritharides L, Kus M, Brown AJ, Jessup W, Dean RT, (1996) Hydroxypropyl-beta-cyclodextrin-mediated efflux of 7-ketocholesterol from macrophage foam cells. J Biol Chem 271: 27450-27455.
20. Li W, Johnson H, Yuan XM, Jonasson L, (2009) 7beta-hydroxycholesterol induces natural killer cell death via oxidative lysosomal destabilization. Free Radic Res 43: 1072-1079.
21. McKinney EF, Lyons PA, Carr EJ, Hollis JL, Jayne DR, et al. (2010) A CD8+ T cell transcription signature predicts prognosis in autoimmune disease. Nat Med 16: 586-591, 581p following 591.
22. Isenberg DA, Rahman A, Allen E, Farewell V, Akil M, et al. (2005) BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford) 44: 902-906.
23. Folch J, Lees M, Sloane Stanley GH, (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226: 497-509.
24. Kim JH, Jittiwat J, Ong WY, Farooqui AA, Jenner AM, (2010) Changes in cholesterol biosynthetic and transport pathways after excitotoxicity. J Neurochem 112: 34-41.
25. Cheng D, Jenner AM, Shui G, Cheong WF, Mitchell TW, et al. (2011) Lipid pathway alterations in Parkinson's disease primary visual cortex. PLoS One 6: e17299.
26. Bligh EG, Dyer WJ, (1959) A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37: 911-917.
27. Shui G, Stebbins JW, Lam BD, Cheong WF, Lam SM, et al. (2011) Comparative plasma lipidome between human and cynomolgus monkey: are plasma polar lipids good biomarkers for diabetic monkeys? PLoS One 6: e19731.
28. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, et al. (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25: 1271-1277.
29. Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, et al. (1993) The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 86: 447-458.
30. Isenberg DA, Gordon C, (2000) From BILAG to BLIPS-disease activity assessment in lupus past, present and future. Lupus 9: 651-654.
31. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35: 630-640.
32. Alarcon GS, Roseman J, Bartolucci AA, Friedman AW, Moulds JM, et al. (1998) Systemic lupus erythematosus in three ethnic groups: II. Features predictive of disease activity early in its course. LUMINA Study Group. Lupus in minority populations, nature versus nurture. Arthritis Rheum 41: 1173-1180.
33. Smith MF Jr, Hiepe F, Dorner T, Burmester G, (2009) Biomarkers as tools for improved diagnostic and therapeutic monitoring in systemic lupus erythematosis. Arthritis Res Ther 11: 255.
34. Francis L, Perl A, (2009) Pharmacotherapy of systemic lupus erythematosus. Expert Opin Pharmacother 10: 1481-1494.
35. Liu CC, Manzi S, Ahearn JM, (2005) Biomarkers for systemic lupus erythematosus: a review and perspective. Curr Opin Rheumatol 17: 543-549.
36. Smith RM, Clatworthy MR, Jayne DR, (2010) Biological therapy for lupus nephritis-tribulations and trials. Nat Rev Rheumatol 6: 547-552.
37. Bjorkhem I, Lovgren-Sandblom A, Piehl F, Khademi M, Pettersson H, et al. (2011) High levels of 15-oxygenated steroids in circulation of patients with multiple sclerosis: fact or fiction? J Lipid Res 52: 170-174.
38. Griffiths WJ, Wang Y, (2010) Are 15-oxygenated sterols present in the human circulation? J Lipid Res 52: 4-5.
39. Bjorkhem I, Diczfalusy U, Olsson T, Russell DW, McDonald JG, et al. (2011) Detecting oxysterols in the human circulation. Nat Immunol 12: 577; author reply 577-578.
40. Descloux E, Durieu I, Cochat P, Vital Durand D, Ninet J, et al. (2008) Paediatric systemic lupus erythematosus: prognostic impact of antiphospholipid antibodies. Rheumatology (Oxford) 47: 183-187.
41. Sorice M, Circella A, Misasi R, Pittoni V, Garofalo T, et al. (2000) Cardiolipin on the surface of apoptotic cells as a possible trigger for antiphospholipids antibodies. Clin Exp Immunol 122: 277-284.
42. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, et al. (1990) A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci U S A 87: 9383-9387.
43. Basu S, (2008) F2-isoprostanes in human health and diseases: from molecular mechanisms to clinical implications. Antioxid Redox Signal 10: 1405-1434.
44. Smith PP, Gordon C, (2010) Systemic lupus erythematosus: clinical presentations. Autoimmun Rev 10: 43-45.
45. Bilzer M, Roggel F, Gerbes AL, (2006) Role of Kupffer cells in host defense and liver disease. Liver Int 26: 1175-1186.
46. Kosugi I, Muro H, Shirasawa H, Ito I, (1992) Endocytosis of soluble IgG immune complex and its transport to lysosomes in hepatic sinusoidal endothelial cells. J Hepatol 16: 106-114.
47. Gronwall C, Akhter E, Oh C, Burlingame RW, Petri M, et al. (2012) IgM autoantibodies to distinct apoptosis-associated antigens correlate with protection from cardiovascular events and renal disease in patients with SLE. Clin Immunol 142: 390-398.
48. Mehrani T, Petri M, (2011) IgM anti-beta2 glycoprotein I is protective against lupus nephritis and renal damage in systemic lupus erythematosus. J Rheumatol 38: 450-453.
49. Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, et al. (2004) Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med 42: 186-191.
50. Shafaati M, Marutle A, Pettersson H, Lovgren-Sandblom A, Olin M, et al. (2011) Marked accumulation of 27-hydroxycholesterol in the brain of Alzheimer patients with the Swedish APP 670/671 mutation. J Lipid Res.
51. Schule R, Siddique T, Deng HX, Yang Y, Donkervoort S, et al. (2010) Marked accumulation of 27-hydroxycholesterol in SPG5 patients with hereditary spastic paresis. J Lipid Res 51: 819-823.
52. Yasunobu Y, Hayashi K, Shingu T, Yamagata T, Kajiyama G, et al. (2001) Coronary atherosclerosis and oxidative stress as reflected by autoantibodies against oxidized low-density lipoprotein and oxysterols. Atherosclerosis 155: 445-453.
53. Leoni V, Lutjohann D, Masterman T, (2005) Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis. J Lipid Res 46: 191-195.
54. Navarra SV, Ishimori ML, Uy EA, Hamijoyo L, Sama J, et al. (2010) Studies of Filipino patients with systemic lupus erythematosus (SLE): Autoantibody profile of first degree relatives. Lupus.
55. Fusaro AE, Fahl K, Cardoso EC, de Brito CA, Jacob CM, et al. (2010) Profile of autoantibodies against phosphorylcholine and cross-reactivity to oxidation-specific neoantigens in selective IgA deficiency with or without autoimmune diseases. J Clin Immunol 30: 872-880.
56. Ortona E, Capozzi A, Colasanti T, Conti F, Alessandri C, et al. (2010) Vimentin/cardiolipin complex as a new antigenic target of the antiphospholipid syndrome. Blood 116: 2960-2967.
57. Abou-Raya A, el-Hallous D, Fayed H, (2004) 8-Isoprostaglandin F2 alpha: a potential index of lipid peroxidation in systemic lupus erythematosus. Clin Invest Med 27: 306-311.
58. Ames PR, Alves J, Murat I, Isenberg DA, Nourooz-Zadeh J, (1999) Oxidative stress in systemic lupus erythematosus and allied conditions with vascular involvement. Rheumatology (Oxford) 38: 529-534.
59. Szodoray P, Tarr T, Tumpek J, Kappelmayer J, Lakos G, et al. (2009) Identification of rare anti-phospholipid/protein co-factor autoantibodies in patients with systemic lupus erythematosus. Autoimmunity 42: 497-506.
60. Zuliani G, Donnorso MP, Bosi C, Passaro A, Dalla Nora E, et al. (2011) Plasma 24S-hydroxycholesterol levels in elderly subjects with late onset Alzheimer's disease or vascular dementia: a case-control study. BMC Neurol 11: 121.